Treatment for Superficial Fungal Infection in Newborns

First-Line Topical Treatment Options

The American Academy of Pediatrics recommends applying nystatin cream or ointment 2-3 times daily for 7-14 days as first-line therapy for superficial cutaneous fungal infections in newborns, with topical clotrimazole 1% as an equally effective alternative 1
For oral candidiasis, the Centers for Disease Control and Prevention suggest administering nystatin oral suspension (100,000 IU/mL): 1 mL four times daily for 7-14 days as first-line treatment 1, 2

The Infectious Diseases Society of America recommends continuing treatment for at least 7-14 days and for a minimum of one week after clinical resolution to prevent recurrence 1
The treatment endpoint should be mycological cure, not merely clinical improvement, according to the American College of Obstetricians and Gynecologists 1, 2

The American Academy of Pediatrics suggests implementing frequent diaper changes with gentle cleansing and thorough drying before medication application, and allowing air exposure to the diaper area when feasible 1
The Centers for Disease Control and Prevention recommend treating both mother and infant simultaneously for breastfeeding-associated thrush, applying miconazole cream to maternal nipples/areola after each feeding while treating the infant 1, 2

The American Academy of Pediatrics states that systemic antifungal therapy is NOT indicated for healthy term infants with localized cutaneous candidiasis, but consider oral fluconazole (3-6 mg/kg daily for 7 days) for resistant cases, extensive or recurrent infections, or immunocompromised infants 1, 2
The Infectious Diseases Society of America recommends amphotericin B deoxycholate (1 mg/kg daily) for 3 weeks for premature neonates with disseminated candidiasis 3

The American Academy of Pediatrics advises against using combination antifungal/corticosteroid preparations (e.g., clotrimazole/betamethasone) in infants, as these cause persistent and recurrent infections 1
The Centers for Disease Control and Prevention warn against discontinuing therapy when symptoms improve but before completing the full 7-14 day course, as premature discontinuation leads to high recurrence rates 1

The American Academy of Pediatrics suggests considering fluconazole prophylaxis (3-6 mg/kg twice weekly for 6 weeks) for neonates with birth weight <1000 g in nurseries with high rates of invasive candidiasis (>10%) 3, 4, 2
The Infectious Diseases Society of America recommends monitoring premature infants receiving nystatin for potential intestinal damage and necrotizing enterocolitis 5, 2

The Centers for Disease Control and Prevention recommend minimizing broad-spectrum antibiotic use, particularly third-generation cephalosporins and carbapenems, which increase fungal colonization risk 5, 1
The American College of Obstetricians and Gynecologists suggests that treatment of maternal vaginal candidiasis prior to delivery may prevent subsequent neonatal colonization 5, 4

Miconazole oral gel, while effective for treating oral thrush, may promote triazole resistance that could diminish the efficacy of future fluconazole therapy in children. 6

In neonatal intensive care units where invasive candidiasis incidence exceeds 10 %, prophylactic oral nystatin (100,000 IU three times daily for 6 weeks) lowers the rate of fungal infections but does not reduce overall mortality and carries a risk of intestinal injury, including necrotizing enterocolitis. 6